Drug repurposing for gastrointestinal stromal tumor

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1299-1309

  Pessetto, Ziyan Y ^a   Weir, Scott J ^a,b,c   Sethi, Geetika ^a,e   Broward, Melinda A ^b,c,d   Godwin, Andrew K ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMSACRINE; AURANOFIN; BORTEZOMIB; CARBIMAZOLE; CHLOROQUINE; CLADRIBINE; CLOFARABINE; CRYSTAL VIOLET; DACTINOMYCIN; DANAZOL; DAUNORUBICIN; DIGITOXIN; DIGOXIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; IDARUBICIN; IMATINIB; MEBENDAZOLE; MITHRAMYCIN; MITOXANTRONE; NAVELBINE; NILOTINIB; OUABAIN; PACLITAXEL; REACTIVE OXYGEN METABOLITE; TENIPOSIDE; THIOREDOXIN REDUCTASE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG REPOSITIONING; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUMOR CELL;

EID: 84880073554     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0968     Document Type: Article

References (50)

1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-86. (Pubitemid 351488293)
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80. (Pubitemid 28067289)
3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10. (Pubitemid 36159485)
4. Rink L, Godwin AK. Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population. Curr Oncol Rep 2009;11:314-21.
5. Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer 2009;48:886-96.
6. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133:141-8.
7. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865-78.
8. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011;223:251-61.
9. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010;116:5126-37.
10. Yang J, Du X, Lazar AJ, Pollock R, Hunt K, Chen K, et al. Genetic aberrations of gastrointestinal stromal tumors. Cancer 2008;113:1532-43.
11. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67 Suppl 1:S25-43.
12. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74. (Pubitemid 46630941)
13. van Glabbeke M, Verweij J, Casali P, Le Cesne A, Hohenberger P, Ray- Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005;23:5795-804.
14. Tarn C, Skorobogatko YV, Taguchi T, Eisenberg B, von Mehren M, Godwin AK. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res 2006;66:5477-86. (Pubitemid 43844976)
15. Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, et al. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Mol Cancer 2009;8:99.
16. Bardsley MR, Horvath VJ, Asuzu DT, Lorincz A, Redelman D, Hayashi Y, et al. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010;139:942-52.
17. Lorincz A, Redelman D, Horvath VJ, Bardsley MR, Chen H, Ordog T. Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology 2008;134:1083-93. (Pubitemid 351451982)
18. Godwin AK. Bench to bedside and back again: personalizing treatment for patients with GIST. Mol Cancer Ther 2011;10:2026-7.
19. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-6. (Pubitemid 47236844)
20. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 2012;72:1055-8.
21. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003;2:699-709.
22. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8. (Pubitemid 32769795)
23. Inglese J, Shamu CE, Guy RK. Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol 2007;3:438-41. (Pubitemid 47080377)
24. Casini A, Messori L. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr Top Med Chem 2011;11:2647-60.
25. Gandin V, Fernandes AP, Rigobello MP, Dani B, Sorrentino F, Tisato F, et al. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol 2010;79:90-101.
26. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61. (Pubitemid 20362087)
27. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, et al. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 2012;72:1126-36.
28. Saggioro D, Rigobello MP, Paloschi L, Folda A, Moggach SA, Parsons S, et al. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem Biol 2007;14:1128-39. (Pubitemid 47599989)
29. Rigobello MP, Bindoli A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling. Methods Enzymol 2010;474:109-22.
30. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk Res 2011;35:243-9.
31. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J, et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 2004;94:1483-91. (Pubitemid 38780321)
32. Kim MR, Chang HS, Kim BH, Kim S, Baek SH, Kim JH, et al. Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell proliferation. Biochem Biophys Res Commun 2003;304:119-24. (Pubitemid 36434204)
33. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995;18:775-94.
34. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008;10:1343-74.
35. Kim JH, Choi W, Lee JH, Jeon SJ, Choi YH, Kim BW, et al. Astaxanthin inhibits H2O2-mediated apoptotic cell death in mouse neural progenitor cells via modulation of P38 and MEK signaling pathways. J Microbiol Biotechnol 2009;19:1355-63.
36. Giorgio M, Trinei M, Migliaccio E, Pelicci PG. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 2007;8:722-8. (Pubitemid 47312827)
37. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006;8:243-70. (Pubitemid 43741296)
38. Rigobello MP, Callegaro MT, Barzon E, Benetti M, Bindoli A. Purification of mitochondrial thioredoxin reductase and its involvement in the redox regulation of membrane permeability. Free Radic Biol Med 1998;24:370-6. (Pubitemid 28008816)
39. Rigobello MP, Folda A, Baldoin MC, Scutari G, Bindoli A. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res 2005;39:687-95. (Pubitemid 40965396)
40. Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Pharmazie 2011;66:440-4.
41. Park SJ, Kim IS. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 2005;146:506-13.
42. Glennas A, Rugstad HE. Ploidity and cell cycle progression during treatment with gold chloride, auranofin and sodium aurothiomalate. Studies on a human epithelial cell line and its sub-strains made resistant to the antiproliferative effects of these gold compounds. Virchows Arch B Cell Pathol Incl Mol Pathol 1985;49:385-93. (Pubitemid 16223628)
43. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000;164:5981-9.
44. Froscio M, Murray AW, Hurst NP. Inhibition of epidermal growth factor binding to HeLa cells by auranofin. Biochem Pharmacol 1987;36:769-72. (Pubitemid 17026099)
45. Froscio M, Murray AW, Hurst NP. Inhibition of protein kinase C activity by the antirheumatic drug aurano fin. Biochem Pharmacol 1989;38: 2087-9. (Pubitemid 19171208)
46. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70:593-9.
47. Champion GD, Cairns DR, Bieri D, Adena MA, Browne CD, Cohen ML, et al. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988;15:28-34. (Pubitemid 18051527)
48. Williams HJ, Ward JR, Egger MJ, Reading JC, Samuelson CO, Altz-Smith M, et al. Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Cooperative systematic studies of rheumatic diseases. Clin Rheumatol 1984;3 Suppl 1:39-50.
49. Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983;3:284-98. (Pubitemid 14243381)
50. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012;18:956-60.